Sommerer Claudia, Hartschuh Wolfgang, Enk Alexander, Meuer Stefan, Zeier Martin, Giese Thomas
Department of Nephrology, University Hospital, University of Heidelberg, Germany.
Clin Transplant. 2008 Sep-Oct;22(5):549-54. doi: 10.1111/j.1399-0012.2008.00819.x. Epub 2008 Apr 3.
Among elderly allograft recipients non-melanoma skin cancer (NMSC) is the most common malignancy. We have previously shown that malignancies are associated with a higher intensity of ciclosporin A (CsA)-induced immunosuppression.
Fifty-five long-term elderly renal transplant patients with a stable transplant function had regular skin examinations. The expression of the nuclear factor of activated T cells (NFAT)-regulated genes (interleukin-2, granulocyte-macrophage colony stimulating-factor, interferon-gamma) was determined by real-time PCR at CsA trough levels and two h after oral intake.
The CsA dose was 2.0 mg/kg (0.95-3.50), with CsA trough level (C0) level 97 microg/L (33-157) and CsA two-h level (C2) 538 microg/L (350-1228). NMSC was diagnosed in 14/55 patients (25.4%). A total of 85.7% of allograft recipients with NMSC were male (p < 0.005). Age, time after transplantation, CsA dose, CsA C0 and C2 level were comparable in both groups. NFAT-regulated gene expression was signficantly lower in patients with skin cancer compared with patients without skin cancer [4.94% (0.91-13.4) vs. 11.6% (3.3-40.8), p < 0.001).
The unproportional high incidence of NMSC in elderly long-term kidney-transplanted patients correlates with a lower NFAT-regulated gene expression which is a surrogate biomarker for a higher degree of functional immunosuppression. Further studies are required to determine whether the reduction of CsA with an increased NFAT-regulated gene expression is associated with a lower NMSC incidence.
在老年同种异体移植受者中,非黑色素瘤皮肤癌(NMSC)是最常见的恶性肿瘤。我们之前已经表明,恶性肿瘤与环孢素A(CsA)诱导的免疫抑制强度较高有关。
55例移植功能稳定的老年长期肾移植患者接受定期皮肤检查。通过实时PCR在CsA谷浓度水平和口服后2小时测定活化T细胞核因子(NFAT)调节基因(白细胞介素-2、粒细胞-巨噬细胞集落刺激因子、干扰素-γ)的表达。
CsA剂量为2.0mg/kg(0.95 - 3.50),CsA谷浓度(C0)水平为97μg/L(33 - 157),CsA两小时浓度(C2)为538μg/L(350 - 1228)。14/55例患者(25.4%)被诊断为NMSC。所有患有NMSC的同种异体移植受者中,85.7%为男性(p < 0.005)。两组患者的年龄、移植后时间、CsA剂量、CsA C0和C2水平相当。与无皮肤癌的患者相比,皮肤癌患者中NFAT调节基因的表达显著降低[4.94%(0.91 - 13.4)对11.6%(3.3 - 40.8),p < 0.001]。
老年长期肾移植患者中NMSC不成比例的高发病率与较低的NFAT调节基因表达相关,NFAT调节基因表达是功能免疫抑制程度较高的替代生物标志物。需要进一步研究以确定随着NFAT调节基因表达增加而减少CsA是否与较低的NMSC发病率相关。